Last reviewed · How we verify

NCT05437939: Mulisa

Adverse Outcomes Following Female Genital Fistula Repair

Active, enrolled Last updated 7 May 2025
What this trial tests

trial in Female Genital Fistula in 802 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 May 2022
Primary endpoint
31 March 2026
31 July 2026

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment802
Start date20 May 2022
Primary completion31 March 2026
Estimated completion31 July 2026
Sites1 location across Uganda

Conditions studied

Sponsor

University of California, San Francisco

Who can join

15 and older, female only, with Female Genital Fistula or Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following genital fistula repair, fistula repair breakdown and recurrence, persistent and incidence incontinence are major adverse outcomes, limiting women's health and wellbeing. Using a prospective design, the investigators seek to identify modifiable risk factors to establish key targets for intervention, followed by qualitative work to refine the feasibility and acceptability of potential intervention strategies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Identifying opportunities for prevention of adverse outcomes following female genital fistula repair: protocol for a mixed-methods study in Uganda.
    El Ayadi AM, Obore S, Kirya F, Miller S, et al · · 2024 · PMID 38178156 · DOI 10.1186/s12978-023-01732-7
  2. Identifying Opportunities for Prevention of Adverse Outcomes Following Female Genital Fistula Repair: Protocol for a Mixed-Methods Study in Uganda
    Ayadi AME, Obore S, Kirya F, Miller S, et al · · 2023 · DOI 10.21203/rs.3.rs-2879899/v1

Verify or expand the search:

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing